Edition:
United States

Aevi Genomic Medicine Inc (GNMX.OQ)

GNMX.OQ on NASDAQ Stock Exchange Global Market

1.35USD
4:00pm EDT
Change (% chg)

$-0.03 (-2.17%)
Prev Close
$1.38
Open
$1.38
Day's High
$1.38
Day's Low
$1.30
Volume
18,001
Avg. Vol
24,586
52-wk High
$2.64
52-wk Low
$0.84

Latest Key Developments (Source: Significant Developments)

Aevi Genomic Medicine Files Prospectus Supplement Related To Offering Of Common Stock
Tuesday, 15 May 2018 08:22am EDT 

May 15 (Reuters) - Aevi Genomic Medicine Inc ::AEVI GENOMIC MEDICINE INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $20 MILLION CO'S COMMON STOCK - SEC FILING.  Full Article

Aevi Genomic Medicine Reports Q4 Loss Per Share $0.13
Tuesday, 13 Mar 2018 07:30am EDT 

March 13 (Reuters) - Aevi Genomic Medicine Inc ::AEVI GENOMIC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.13.Q4 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.AEVI GENOMIC MEDICINE - HAD CASH AND CASH EQUIVALENTS OF $33.73 MILLION AT DECEMBER 31, 2017​.‍EXPECTS CURRENT CASH BALANCE TO FUND OPERATIONS INTO EARLY 2019​.  Full Article

Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co
Wednesday, 7 Mar 2018 08:00am EST 

March 7 (Reuters) - Aevi Genomic Medicine Inc ::AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD.AEVI GENOMIC MEDICINE - SIGNING OF OPTION AGREEMENT FOR EARLY STAGE MONOCLONAL ANTIBODY PROGRAM IN AN ULTRA-ORPHAN PEDIATRIC INDICATION.AEVI GENOMIC MEDICINE INC - FINANCIAL AND OTHER TERMS OF DEAL WERE NOT DISCLOSED.  Full Article

Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders
Friday, 8 Dec 2017 08:46am EST 

Dec 8 (Reuters) - Aevi Genomic Medicine Inc ::AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Aevi Genomic Medicine Q3 loss per share $0.23
Thursday, 2 Nov 2017 09:27am EDT 

Nov 2 (Reuters) - Aevi Genomic Medicine Inc ::Aevi Genomic Medicine reports third quarter 2017 financial results.Q3 loss per share $0.23.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Aevi Genomic Medicine Inc - ‍company had cash and cash equivalents of $14.96 million at September 30, 2017​.Aevi Genomic Medicine Inc- ‍expects current cash balance, including proceeds from pipe offering, to fund operations into early 2019​.  Full Article

Aevi Genomic Medicine announces private placement
Thursday, 10 Aug 2017 06:15am EDT 

Aug 10 (Reuters) - Aevi Genomic Medicine Inc ::Aevi Genomic Medicine announces agreement for $28 million private placement.Aevi genomic medicine - will sell 22.2 million shares of common stock with warrants to purchase approximately 4.0 million additional shares of stock​.Aevi genomic medicine inc - ‍chop foundation led financing, with additional participation by other undisclosed existing blue-chip investors​.Aevi genomic - to use proceeds of pipe for development of 2 lead clinical programs, to support collaboration with children's hospital of Philadelphia​.Aevi genomic medicine inc - Chop Foundation has committed to provide up to an additional $5.0 million of equity financing through June 30, 2018.  Full Article

Aevi Genomic Medicine reports Q2 loss per share of $0.22
Wednesday, 9 Aug 2017 05:31pm EDT 

Aug 9 (Reuters) - Aevi Genomic Medicine Inc :Aevi Genomic Medicine reports second quarter 2017 financial results.Q2 loss per share $0.22.Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.‍Company expects its reported cash balance to fund operations into Q2 of 2018​.‍Company had cash and cash equivalents of $21.36 million at June 30, 2017​.  Full Article

Aevi Genomic Medicine reprts qtrly loss per share of $0.22
Wednesday, 9 Aug 2017 04:22pm EDT 

Aug 9 (Reuters) - Aevi Genomic Medicine Inc :Qtrly diluted loss per share $0.22.  Full Article

Adage Capital Partners report a passive stake of 5.56 pct in Aevi Genomic Medicine,
Friday, 2 Jun 2017 04:53pm EDT 

June 2 (Reuters) - Aevi Genomic Medicine Inc :Adage Capital Partners reports a passive stake of 5.56 pct in Aevi Genomic Medicine, as of May 24 - SEC filing.  Full Article

Aevi Genomic Medicine posts Q1 loss per share $0.29
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Aevi Genomic Medicine Inc :Aevi Genomic Medicine announces plans to initiate Phase 2 clinical trial to confirm genetic responders to AEVI-001 and first quarter 2017 operating results.Q1 loss per share $0.29.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Aevi Genomic Medicine Inc - patient recruitment for AEVI-002 in severe pediatric onset crohn's disease to begin during 2Q 2017.Aevi Genomic Medicine - expect to initiate Phase 2 trial of AEVI-001 in patients with identified genetic subset during second half of 2017.Aevi Genomic Medicine Inc - expects its reported cash balance to fund operations through end of q2 2018.  Full Article

BRIEF-Aevi Genomic Medicine Q1 Loss Per Share $0.15

* AEVI GENOMIC MEDICINE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE